Interleukin-17A (IL-17A), a major effector cytokine secreted by T helper 17 (Th17) cells, is elevated in atherosclerosis lesions. The purpose of this study was to assess the role of IL-17A in the pathogenesis of atherosclerosis. To measure the expression of adhesion molecules, human umbilical vein endothelial cells (HUVECs) and U937 cells were stimulated with IL-17A. Western blot and real-time polymerase chain reaction analyses revealed that intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression in HUVECs, and very late antigen-4 (VLA-4), lymphocyte function-associated antigen-1 (LFA-1) and macrophage-1 antigen (MAC-1) expression in U937 cells was upregulated by IL-17A. Furthermore, IL-17A stimulation resulted in mRNA and protein expression of scavenger receptor (LOX-1) in phorbol 12-myristate 13-acetate (PMA)-activated U937 cells. Oil Red O also demonstrated that IL-17A enhanced foam cell formation by PMA-activated U937 cells induced by oxidized low-density lipoprotein (ox-LDL), and this enhancement of ox-LDL-induced foam cell formation in IL-17A-treated U937 cells was downregulated by transfection of LOX-1 siRNA. These results indicated that IL-17A induced the expression of adhesion molecules, promoted the adherence of monocytes to vascular endothelial cells. IL-17A also stimulated ox-LDL-induced foam cell formation via upregulation of LOX-1 in activated macrophages. IL-17A may be responsible for the pathogenesis of atherosclerosis by inducing the adhesion of leukocytes to vascular endothelium and foam cell formation.
AslanianAM, CharoIF. 2006. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation, 114(6):583–590.
3.
BenagianoM, BorghiMO, RomagnoliJ, MahlerM, Della BellaC, GrassiA, CapitaniN, EmmiG, TroiloA, SilvestriE, EmmiL, AlnwaisriH, BitettiJ, TapinassiS, PriscoD, BaldariCT, MeroniPL, D'EliosMM. 2019. Interleukin-17/interleukin-21 and interferon-g producing T cells specific for beta2 glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica [Epub ahead of print]; DOI: 10.3324/haematol.2018.209536.
4.
BenagianoM, MunariF, CiervoA, AmedeiA, PaccaniSR, ManciniF, FerrariM, Della BellaC, UliviC, D'EliosS, BaldariCT, PriscoD, de BernardM, D'EliosMM. 2012. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A, 109(4):1222–1227.
5.
EndemannG, StantonLW, MaddenKS, BryantCM, WhiteRT, ProtterAA. 1993. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem, 268(16):11811–11816.
6.
ErbelC, ChenL, BeaF, WanglerS, CelikS, LasitschkaF, WangY, BocklerD, KatusHA, DenglerTJ. 2009. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol, 183(12):8167–8175.
7.
ErbelC, DenglerTJ, WanglerS, LasitschkaF, BeaF, WambsganssN, HakimiM, BocklerD, KatusHA, GleissnerCA. 2011. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol, 106(1):125–134.
8.
FebbraioM, PodrezEA, SmithJD, HajjarDP, HazenSL, HoffHF, SharmaK, SilversteinRL. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest, 105(8):1049–1056.
9.
FossiezF, DjossouO, ChomaratP, Flores-RomoL, Ait-YahiaS, MaatC, PinJJ, GarroneP, GarciaE, SaelandS, BlanchardD, GaillardC, Das MahapatraB, RouvierE, GolsteinP, BanchereauJ, LebecqueS. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med, 183(6):2593–2603.
10.
GalkinaE, LeyK. 2009. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol, 27:165–197.
11.
HanssonGK, LibbyP. 2006. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 6(7):508–519.
KunjathoorVV, FebbraioM, PodrezEA, MooreKJ, AnderssonL, KoehnS, RheeJS, SilversteinR, HoffHF, FreemanMW. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem, 277(51):49982–49988.
22.
LeyK, LaudannaC, CybulskyMI, NoursharghS. 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol, 7(9):678–689.
23.
LiL, SawamuraT, RenierG. 2004. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res, 94(7):892–901.
24.
LiuG, WuH, ChenL, XuJ, WangM, LiD, LuP. 2017. Effects of interleukin-17 on human retinal vascular endothelial cell capillary tube formation in vitro. Mol Med Rep, 16(1):865–872.
25.
LiuM, LiX, SunR, ZengYI, ChenS, ZhangP. 2016. Vitamin D nutritional status and the risk for cardiovascular disease. Exp Ther Med, 11(4):1189–1193.
26.
LiuYR, ChenJJ, DaiM. 2014. Paeonol protects rat vascular endothelial cells from ox-LDL-induced injury in vitro via downregulating microRNA-21 expression and TNF-alpha release. Acta Pharmacol Sin, 35(4):483–488.
MooreKJ, KunjathoorVV, KoehnSL, ManningJJ, TsengAA, SilverJM, McKeeM, FreemanMW. 2005. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest, 115(8):2192–2201.
31.
NumasakiM, TsukamotoH, TomiokaY, NishiokaY, OhruiT. 2016. A heterodimeric cytokine, consisting of IL-17A and IL-17F, promotes migration and capillary-like tube formation of human vascular endothelial cells. Tohoku J Exp Med, 240(1):47–56.
32.
OnishiRM, GaffenSL. 2010. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology, 129(3):311–321.
SimonJN, DuglanD, CasadeiB, CarnicerR. 2014. Nitric oxide synthase regulation of cardiac excitation-contraction coupling in health and disease. J Mol Cell Cardiol, 73:80–91.
40.
StaryHC, ChandlerAB, GlagovS, GuytonJR, InsullWJr., RosenfeldME, SchafferSA, SchwartzCJ, WagnerWD, WisslerRW.1994. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 89(5):2462–2478.
41.
SuzukiE, MellinsED, GershwinME, NestleFO, AdamopoulosIE. 2014. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev, 13(4–5):496–502.
42.
TedguiA, MallatZ. 2006. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 86(2):515–581.
43.
ThomasSR, WittingPK, DrummondGR. 2008. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal, 10(10):1713–1765.
44.
WeberC, NoelsH. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 17(11):1410–1422.
45.
YamadaY, DoiT, HamakuboT, KodamaT. 1998. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci, 54(7):628–640.
46.
YangJZ, LiY, SunLX, FangJ, KongLJ, ZhangJQ. 2014. Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients. Pathol Res Pract, 210(9):586–590.
47.
YaoW, HuangL, SunQ, YangL, TangL, MengG, XuX, ZhangW. 2016. The inhibition of macrophage foam cell formation by tetrahydroxystilbene glucoside is driven by suppressing vimentin cytoskeleton. Biomed Pharmacother, 83:1132–1140.
48.
ZhangH, LiangB, LiT, ZhouY, ShangD, DuZ. 2018. Orexin A suppresses oxidized LDL induced endothelial cell inflammation via MAPK p38 and NF-kappaB signaling pathway. IUBMB Life, 70(10):961–968.
49.
ZhangS, GuoS, GaoXB, LiuA, JiangW, ChenX, YangP, LiuLN, ShiL, ZhangY. 2019. Matrine attenuates high-fat diet-induced in vivo and ox-LDL-induced in vitro vascular injury by regulating the PKCalpha/eNOS and PI3K/Akt/eNOS pathways. J Cell Mol Med, 23(4):2731–2743.
